1170 Development of a fusion protein bispecific for a CMV-specific TCR and CD19 which selectively ac...
1170 Development of a fusion protein bispecific for a CMV-specific TCR and CD19 which selectively activates and expands CMV-specific CTLs and redirects them to eliminate B cell leukemia cells
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundWe constructed RediTac, novel biologics designed to selectively activate and expand virus-specific CD8 T cells (CTL) and redirect them to eliminate cancer cells (figure 1A). RediTac utilize an Fc-fusion protein scaffold to dimerize an HLA-A2 pMHC linked to cancer-targeting scFvs (figure 1B). The pMHC presents a tethered virus peptide to t...
Alternative Titles
Full title
1170 Development of a fusion protein bispecific for a CMV-specific TCR and CD19 which selectively activates and expands CMV-specific CTLs and redirects them to eliminate B cell leukemia cells
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_8efb06b8ead147f1a7d91340f55c5509
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8efb06b8ead147f1a7d91340f55c5509
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2023-SITC2023.1170
